Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
26 July 2021 | Story Nonsindiso Qwabe | Photo Nonsindiso Qwabe
On top of the Drakensberg. The ARU and Witsieshoek Mountain Lodge research team are, from the left: Grant Martin, Dr Ralph Clark, Jan van Niekerk, Prof Aliza le Roux, Prof Peter Taylor, and Dr Sandy Steenhuisen.

All mountains around the world have native and non-native species that are expanding their ranges quite dramatically; however, little research has been conducted towards understanding the long-term redistribution of species and the effects of global change on biodiversity.


The Afromontane Research Unit (ARU) on the University of the Free State Qwaqwa Campus – as part of the Mountain Invasion Research Network – has secured a two-year EU Horizon 2020 project under the Department of Science and Innovation, which will be looking at the mechanisms underlying the success and impact of range-expanding species on biodiversity and ecosystem functioning.

On Monday 19 July 2021, the ARU took a few of its researchers on a scenic helicopter ride to the summit of the Drakensberg for an alpine field-experiment site inspection of the Mont-aux-Sources peak, one of the highest sections of the Drakensberg range. This site has been identified for the project which the research unit will be leading on mountain research.

ARU Director, Dr Ralph Clark, said the project would explore the effects of global change, biological invasions (when species invade new geographic regions), as well as climate and land-use change. He said experiments were needed to explore the various possibilities and to test the extent to which species respond to experimental treatments. The project would therefore be conducting experiments for two years using open-top chambers – causing an increase in temperature of 3 or 4 degrees to what you find naturally – on plant species from lower down to the top of the mountain, to see how they function. “This will give us an idea of whether they will be able to survive in global warming scenarios. If temperatures get warmer, we might start seeing a lot of plants up here that we wouldn’t otherwise find here.”

Dr Clark said little is known about the long-term monitoring of species distribution and the effects of global change. Implementing the project in the Maloti-Drakensberg alpine area will therefore put the area in the global mountain research arena. The elevational gradient in the Maloti-Drakensberg Mountains provides space to explore the key processes underlying the variation in species elevation with climate change. “One of the things we don’t know much about are alpine systems. We are hoping to establish a long-term alpine research site and try to add as many studies as we can. The more science we can bring up here, the more we can know about mountain life. What happens on mountains has a lot of impact on social dynamics.

“This project is looking to see what is driving range expansion. Every mountain has its own context. In the Swiss alpine, fires are not a big factor, but fires are one of the biggest factors on our mountains. Some of our native and non-native species are therefore fire-driven, so as fire increases, you might have them spreading faster.”

Listen to the article:

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept